Industry News
Biotechnology Industry News
As Sanofi counts down the days…
As Sanofi counts down the days before its new leader arrives, the pharma's CFO acknowledged to Fierce that there have been a “certain number of setbacks.”
Just a few months after ripping up…
Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, Eli Lilly has now thrown out the rest of the pact, too.
Kurma Partners has closed its…
Kurma Partners has closed its fourth biotech venture capital fund after raising 215 million euros ($252 million) to support European startups.
A little over a year after…
A little over a year after reabsorbing its anticoagulant abelacimab, Novartis has now terminated two phase 3 trials for the antibody.
Kyverna Therapeutics has unveiled…
Kyverna Therapeutics has unveiled the full results from its registrational trial of miv-cel in stiff person syndrome (SPS), providing a comprehensive look at what could become the first-ever CAR-T therapy approved for an autoimmune disease.
Roche has shared details of…
Roche has shared details of fatalities in its phase 3 relapsing multiple sclerosis trials, revealing that deaths from infections, diabetes complications and an accident contributed to an imbalance between the fenebrutinib and control cohorts.
A pair of Sage veterans has…
A pair of Sage veterans has launched a neurology-focused startup armed with $106 million and a clinical-stage pipeline of assets licensed from Eisai and Hansoh.
Gene therapy biotech Ray…
Gene therapy biotech Ray Therapeutics has announced the closing of a $125 million series B financing to support the company’s vision restoration candidates for patients with retinal degeneration.
Gilead and Arcus’ domvanalimab,…
Gilead and Arcus' domvanalimab, one of the last anti-TIGIT antibodies still standing, has failed another trial—leading Gilead to pull further away from their once wide-ranging collaboration.
Replimune is saying goodbye to a…
Replimune is saying goodbye to a further 161 staffers across two Massachusetts sites.
Since its 2014 founding, Zai Lab…
Since its 2014 founding, Zai Lab has built its business by licensing drugs from Big Pharma. But in the last three years, the company has sought to leverage its footholds in China and the U.S.
Eli Lilly is picking up its second…
Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia Therapeutics and its phase 1-stage myeloma therapy.
Following its move to secure…
Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building on an existing partnership with local drugmaker TJ Biopharma.
Novo Nordisk is gearing up to…
Novo Nordisk is gearing up to submit its rare blood disorder drug to the FDA after the former Forma Therapeutics asset reduced a painful complication of sickle cell disease (SCD) in a phase 3 study.
A phase 2 trial combining…
A phase 2 trial combining Agenus’ and MiNK Therapeutics’ cancer candidates has missed its primary endpoint. But with the study generating early evidence the cocktail improves survival, the biotechs said the data support further assessment
President Donald Trump has ordered…
President Donald Trump has ordered the FDA to perform priority reviews of psychedelic drugs as part of a push to clear barriers to access to treatments for serious mental illnesses.
In another sign that the biotech…
In another sign that the biotech IPO market is heating back up, Odyssey Therapeutics has made a fresh announcement of its intention to go public.
After dropping headline-grabbing…
After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib, last Monday, Revolution Medicines is not resting on its laurels. The Bay Area biotech spent several recent days in San Diego highlighting earlier
Asked by Fierce if he’d consider…
Asked by Fierce if he'd consider returning to the FDA, Pazdur said he wouldn't serve again under the Trump administration "for obvious reasons."
The agreement fulfills several…
The agreement fulfills several ambitions for UCB. Besides building its epilepsy position, it "marks a strategic expansion into regenerative medicine and advanced therapies," the Belgian biopharma explained.